CN106795173B - 作为ftl3和jak抑制剂的大环n-芳基-2-氨基-4-芳基-嘧啶聚醚的衍生物 - Google Patents

作为ftl3和jak抑制剂的大环n-芳基-2-氨基-4-芳基-嘧啶聚醚的衍生物 Download PDF

Info

Publication number
CN106795173B
CN106795173B CN201580054324.6A CN201580054324A CN106795173B CN 106795173 B CN106795173 B CN 106795173B CN 201580054324 A CN201580054324 A CN 201580054324A CN 106795173 B CN106795173 B CN 106795173B
Authority
CN
China
Prior art keywords
fragrance
compound
alkyl
group
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580054324.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN106795173A (zh
Inventor
E·B·贝拉卢纳
S·格里索尼
B·戈梅斯
P·施米特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CN106795173A publication Critical patent/CN106795173A/zh
Application granted granted Critical
Publication of CN106795173B publication Critical patent/CN106795173B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580054324.6A 2014-09-02 2015-09-02 作为ftl3和jak抑制剂的大环n-芳基-2-氨基-4-芳基-嘧啶聚醚的衍生物 Expired - Fee Related CN106795173B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1458203A FR3025199B1 (fr) 2014-09-02 2014-09-02 Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques
FR1458203 2014-09-02
PCT/EP2015/070066 WO2016034634A1 (fr) 2014-09-02 2015-09-02 Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques comme inhibiteurs de la ftl3 and jak

Publications (2)

Publication Number Publication Date
CN106795173A CN106795173A (zh) 2017-05-31
CN106795173B true CN106795173B (zh) 2019-05-31

Family

ID=51842564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580054324.6A Expired - Fee Related CN106795173B (zh) 2014-09-02 2015-09-02 作为ftl3和jak抑制剂的大环n-芳基-2-氨基-4-芳基-嘧啶聚醚的衍生物

Country Status (14)

Country Link
US (1) US20170281622A1 (https=)
EP (1) EP3189060B1 (https=)
JP (1) JP2017532299A (https=)
CN (1) CN106795173B (https=)
BR (1) BR112017003881A2 (https=)
DK (1) DK3189060T3 (https=)
ES (1) ES2686828T3 (https=)
FR (1) FR3025199B1 (https=)
HU (1) HUE040648T2 (https=)
MX (1) MX2017002627A (https=)
PL (1) PL3189060T3 (https=)
RU (1) RU2017108932A (https=)
TR (1) TR201813294T4 (https=)
WO (1) WO2016034634A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021211974A1 (en) * 2020-04-18 2021-10-21 Inipharm, Inc. Hsd17b13 inhibitors and uses thereof
CN113735879B (zh) * 2020-05-27 2022-05-17 百极弘烨（广东）医药科技有限公司 一种大环jak抑制剂及其应用
CN113735856A (zh) * 2020-05-29 2021-12-03 百极弘烨(南通)医药科技有限公司 大环jak抑制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360751A (zh) * 2005-11-16 2009-02-04 S*Bio私人有限公司 氧连接的嘧啶衍生物
CN102143953A (zh) * 2008-03-26 2011-08-03 诺丁汉大学 嘧啶、三嗪类化合物以及它们作为药剂的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360751A (zh) * 2005-11-16 2009-02-04 S*Bio私人有限公司 氧连接的嘧啶衍生物
CN102143953A (zh) * 2008-03-26 2011-08-03 诺丁汉大学 嘧啶、三嗪类化合物以及它们作为药剂的用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14……heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase;Anthony D. William,等;《Journal of Medicinal Chemistry》;20110523;第54卷(第13期);第4638-4658页 *
Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3);Anthony D. William，等;《Journal of Medicinal Chemistry》;20111208;第55卷(第1期);第437-450页 *
Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine;Anders Poulsen，等;《J Comput Aided Mol Des》;20120422;第26卷(第4期);第437-450页 *

Also Published As

Publication number Publication date
EP3189060A1 (fr) 2017-07-12
WO2016034634A1 (fr) 2016-03-10
DK3189060T3 (en) 2018-10-01
JP2017532299A (ja) 2017-11-02
MX2017002627A (es) 2017-09-19
HUE040648T2 (hu) 2019-03-28
RU2017108932A (ru) 2018-10-03
ES2686828T3 (es) 2018-10-22
TR201813294T4 (tr) 2018-11-21
PL3189060T3 (pl) 2019-03-29
CN106795173A (zh) 2017-05-31
RU2017108932A3 (https=) 2019-01-23
BR112017003881A2 (pt) 2017-12-26
FR3025199B1 (fr) 2016-09-23
FR3025199A1 (fr) 2016-03-04
US20170281622A1 (en) 2017-10-05
EP3189060B1 (fr) 2018-06-20

Similar Documents

Publication Publication Date Title
TWI911172B (zh) Kras g12c突變體之小分子抑制劑
AU2022258377B2 (en) Ring-modified proline short peptide compound and use thereof
CN113024544B (zh) 一种含氰基并杂环化合物及其用途
CN110036014B (zh) 一种具有axl抑制活性的化合物及其制备和应用
CN112745335B (zh) 一种三并杂环化合物及其用途
TWI693220B (zh) １,３,４-噻二唑化合物及其用於治療癌症之用途
CN112707905B (zh) 一种三并杂环化合物及其制备方法和用途
BR112018014536B1 (pt) Derivados de amônio, processo para sua preparação, composição farmacêutica contendo os mesmos, combinação e seu uso
WO2020160180A1 (en) Compounds and uses thereof
EA029126B1 (ru) Ингибиторы ido
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
CN112851663B (zh) 一种并杂环化合物及其用途
TW201733587A (zh) 1,3,4-噻二唑化合物及其在治療癌症中之用途
CN114249712A (zh) 嘧啶基衍生物、其制备方法及其用途
CN121652220A (zh) 含有三氟甲磺酰基的化合物
CN106795173B (zh) 作为ftl3和jak抑制剂的大环n-芳基-2-氨基-4-芳基-嘧啶聚醚的衍生物
TW201730188A (zh) 1,3,4-噻二唑化合物及其在治療癌症中之用途
TW201731837A (zh) 雙嗒 化合物及它們在治療癌症中之用途
CN111362946A (zh) 一种药物化合物及其组合物和应用
CN121537408A (zh) 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物
WO2022095909A1 (zh) 用作ntrk激酶抑制剂的化合物及其应用
CN106715445B (zh) 作为ftl3和jak抑制剂的大环n-芳基-三环嘧啶-2-胺聚醚的衍生物
TW202322812A (zh) 吡唑［３，４－ｄ］嘧啶－３－酮類化合物、包含其的藥物組合物及其醫藥用途
HK1233633A1 (en) Derivatives of macrocyclic n-aryl-2-amino-4-aryl-pyrimidine polyethers as inhibitors of ftl3 and jak
JP7851393B2 (ja) 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1233633

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190531

Termination date: 20190902

CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1233633

Country of ref document: HK